Thursday, January 20, 2022 8:44:31 PM
I'll keep them in mind, but I did go all in with NVACU these last 2 weeks, so capital is tied up for a bit.
I see NorthView as a quick in and out, with the possibility to double or triple the investment in a very short time.
I have no intentions of holding a share, a warrant, or a right more than 3 or 4 days after they PR a target.
Really, with the amount of shares I picked up, I should be able to get out in less than a day.
Good luck with all your investments.
I see NorthView as a quick in and out, with the possibility to double or triple the investment in a very short time.
I have no intentions of holding a share, a warrant, or a right more than 3 or 4 days after they PR a target.
Really, with the amount of shares I picked up, I should be able to get out in less than a day.
Good luck with all your investments.
Please note that my posts are for discussion only. They should NOT BE CONSIDERED AS ADVICE FOR YOUR OWN PERSONAL INVESTMENT CHOICES. ALWAYS do your own DD and feel free to question or validate my posts at anytime.
Recent PFSA News
- Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform • GlobeNewswire Inc. • 04/06/2026 10:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/04/2026 05:15:14 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/02/2026 02:10:43 PM
- Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering • GlobeNewswire Inc. • 02/27/2026 02:15:00 PM
- Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance • GlobeNewswire Inc. • 02/19/2026 01:30:00 PM
- Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies • GlobeNewswire Inc. • 02/13/2026 01:30:00 PM
- Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies • GlobeNewswire Inc. • 02/12/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:00:47 PM
- Profusa Announces 1-for-75 Reverse Stock Split • GlobeNewswire Inc. • 02/05/2026 01:00:00 PM
- Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 • GlobeNewswire Inc. • 01/29/2026 01:00:00 PM
- Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue • GlobeNewswire Inc. • 01/16/2026 12:30:00 PM
- Profusa Adds Leading Greek Vascular Surgeon to Customer Base • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Profusa Bolsters European Commercial Network with New French Distributor, MedSell • GlobeNewswire Inc. • 12/31/2025 12:30:00 PM
- Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 • GlobeNewswire Inc. • 12/30/2025 12:30:00 PM
- Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 • GlobeNewswire Inc. • 12/11/2025 01:30:00 PM
- Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 • GlobeNewswire Inc. • 11/24/2025 01:15:00 PM
- Profusa Announces Third Quarter Business and Financial Highlights • GlobeNewswire Inc. • 11/19/2025 10:44:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/19/2025 10:19:05 PM
- Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches • GlobeNewswire Inc. • 10/30/2025 11:30:00 AM
- Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026 • GlobeNewswire Inc. • 10/28/2025 12:30:00 PM
- Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe • GlobeNewswire Inc. • 10/22/2025 12:30:00 PM
- Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe • GlobeNewswire Inc. • 10/15/2025 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/09/2025 09:20:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/07/2025 08:30:26 PM
